Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neuren Pharmaceuticals (NEU) has provided updates regarding 2019 and its positive outlook heading into 2020
  • In September, the company achieved two significant milestones with its U.S. partner beginning its phase 3 trial and the U.S. FDA granting all three of its orphan drug applications for NNZ-2591
  • Now that NNZ-2591 has been granted in Europe, Neuren now has patents until 2034 in the U.S., Europe and Japan
  • Neuren is currently up 4.35 per cent with shares trading for $2.40 apiece

Neuren Pharmaceuticals (NEU) has provided updates regarding 2019 and its positive outlook heading into 2020.

“In September we highlighted two very important milestones that were anticipated for the fourth quarter of 2019,” Executive Chairman Richard Treagus commented.

These two milestones include its U.S. partner ACADIA beginning the LAVENDER phase 3 trial in Rett Syndrome, and the U.S. Food and Drug Administration granting all three of its orphan drug applications for Phelan-McDermid, Angelman and Pitt Hopkins syndromes.

Now that NNZ-2591 has been granted in Europe, Neuren now has patents to 2034 in each of the key markets of the U.S., Europe and Japan.

Over the course of 2019 Neuren, assisted by Torreya, has actively engaged with third parties both in and outside of the U.S. to evaluate potential transactions.

The company has also received a number of proposals which have led to more detailed discussions. Throughout these discussions, Neuren has remained clear on what it considers to be an acceptable range of possible outcomes.

In recent weeks the process has advanced further with a level of interest that the Neuren Board regards as meaningful and appropriate.

While there is no certainty as of yet, these discussions form a good basis to extend the Torreya process into 2020.

Neuren is now approaching the end of the year in a strong position, advancing two valuable drugs to treat five childhood disorders for which there are currently no approved therapies.

Neuren is currently up 4.35 per cent with shares trading for $2.40 at 12:38 pm AEDT.

NEU by the numbers
More From The Market Herald
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp Health (ASX:RAP) achieves regulatory approvals for cough counter application

ResApp Health (RAP) has achieved Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application.
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.